

MIDDLE EAST OBESITY, BARIATRIC SURGERY AND ENDOCRINOLOGY CONGRESS

June 25-26, 2018 Dubai, UAE

X-cmark for detection of cardiac biomarkers in obese and overweight people

Vineeta Sharma

Xpedite Pharma Solutions, USA

Obesity associated metabolic and cardiovascular disorders are the leading cause of mortality in developing and developed countries. One third of the US population is either overweight or obese, according to WHO, by 2030, 50% of the US population will be obese. Obesity is associated with an increased risk of cardiovascular disorders, metabolic disorders and cancer. Obesity associated disorders put enormous burden on health care system, in US associated burden is approximately \$147 billion to \$210 billion per annum and in UK it is approximately £2.5 billion per annum. Cardiac events such as stroke, atherosclerosis and myocardial infraction are the leading cause of death in both men and women, however, obese men have three to four times higher risk of developing a cardiovascular problem compared to women. Effective and early screening of cardiac biomarkers can reduce mortality rate. Xpedite has developed a rapid screening test to identify four cardiac biomarkers from plasma samples. Our rapid screening test, X-cmark requires only a drop of blood and generates results within few minutes. Initial validation studies have confirmed the sensitivity as high as 95% and specificity upto 96%. This test outperforms most of the traditional immunochemical screening assays and offers an ease of testing at remote or resource poor settings. X-cmark is approximately three times cheaper compared to traditional blood tests. To clinically validate the test, we are planning to test 4 patient groups (gp1; myocardial infraction patients, gp2; obese+high LDL and lipids, gp3; overweight+high LDL and lipids, gp4; normal weight+high LDL and lipids) and a control group (healthy individuals); each group includes 10 male patients or controls. To summarize, X-cmark provides rapid detection of cardiac biomarkers and can be used by hospital staff or lab technicians without any specialized training. Global cost of cardiovascular disorders is expected to reach up to US \$1,044 billion by 2030; early and precise detection of cardiac biomarkers can reduce this cost as much as 25-30%. We are expecting to capture 16% percent cardiac biomarker market share by year 2020.

Biography

Vineeta Sharma is the Founder and Principal Consultant at Xpedite Pharma Solutions, USA. She holds a PhD from AIIMS, New Delhi and Postdoctoral training from University of Michigan and UCSF Benioff Children's Hospital, Oakland. She has published several peer-reviewed articles and book chapters in the field of metabolic disorders, obesity, diabetes, hematology and gene therapy.

vsharma@xpeditepharmasolution.com